Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : Britain's AstraZeneca launches $1 billion China investment fund with CICC

share with twitter share with LinkedIn share with facebook
share via e-mail
11/06/2019 | 05:01am EST
Pascal Soriot, chief executive officer of pharmaceutical company AstraZeneca, attends an interview with Reuters in Shanghai

SHANGHAI (Reuters) - AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country.

SHANGHAI (Reuters) - AstraZeneca said it is lauching a new fund with China International Capital Corporation (CICC) to invest $1 billion (£777.00 million) in China's healthcare sector, as it expands its research work in the country.

The fund would look to invest in Chinese firms, with companies in a life-sciences park it helped open in the eastern city of Wuxi last year to be among its first beneficiaries, the British drugmaker's chief executive officer, Pascal Soriot, told Reuters.

AstraZeneca was a minority partner in the fund and would mainly play an advisory role in selecting investments and supporting the firms, he said. The companies did not disclose financial details of the deal.

"It's a substantial investment on our side, but also our financial partners," Soriot said of the agreement, to be signed with the Chinese investment bank CICC on the sidelines of the China International Import Expo on Wednesday.

"We can help choose some of those investments but we can also help along the way the startup companies, develop products and find their way around the world" he said, describing it as AstraZeneca's largest-scale healthcare industrial fund.

The company also planned to expand an existing research and development centre in Shanghai from 450 employees to 1,000, and establish a new artifical intellgience innovation centre in the city.

Western drugmakers have profited from partnerships in China, where AstraZeneca's sales have doubled since 2012, as well as a softening in the regulatory environment for pharmaceutical firms.

But the government has also been trying to slash drug prices, changing the playing field as many firms had relied in the past on selling older drugs at premium prices. In September, China also expanded a pilot bulk-buying programme to the entire country in an attempt to negotiate lower prices from drug manufacturers.

Soirot said these were both factors in AstraZeneca's decision to make those investments in China, as the price pressures were encouraging companies to create new drugs that the government was approving and reimbursing at a faster pace.

AstraZeneca, he said, wanted to start making drugs it could export globally from China. Areas of opportunity included oncology and respiratory diseases.

"Historically, until today, our Chinese team has been developing global products for the Chinese market. We want now the Chinese team to take the global leadership on some projects," he said.

(Reporting by Brenda Goh; Editing by Stephen Coates)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA -1.01% 7248 Delayed Quote.23.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
11/17ASTRAZENECA :  Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevatio..
11/17ASTRAZENECA : Consistent Effects of FARXIGA in Heart Failure Patients With Reduc..
11/15ASTRAZENECA : Type-2 Diabetes Drug Qtrilmet Approved in the EU
11/15ASTRAZENECA : Qtrilmet approved in the EU for treatment of T2D
11/14ASTRAZENECA : Launches Diabetes Can Break Your Heart
11/14Merck, AstraZeneca Get FDA Priority Review for Selumetinib in NF1
11/14MERCK AND : US FDA accepts regulatory submission for selumetinib in neurofibroma..
11/13LONDON STOCK EXCHANGE : FTSE dips on murky trade view; Tullow tanks on mid-caps
11/11ROXADUSTAT POOLED ANALYSES : no increased CV risk
11/08FibroGen, AstraZeneca Up After Roxadustat Data
More news
Financials (USD)
Sales 2019 24 471 M
EBIT 2019 6 592 M
Net income 2019 2 125 M
Debt 2019 11 723 M
Yield 2019 3,00%
P/E ratio 2019 55,8x
P/E ratio 2020 37,4x
EV / Sales2019 5,49x
EV / Sales2020 4,99x
Capitalization 123 B
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 99,59  $
Last Close Price 93,51  $
Spread / Highest target 44,4%
Spread / Average Target 6,50%
Spread / Lowest Target -24,2%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA23.41%122 645
JOHNSON & JOHNSON4.56%355 145
ROCHE HOLDING AG20.79%255 382
MERCK AND COMPANY11.11%216 154
PFIZER-14.59%206 312
NOVARTIS18.75%202 726